• Mesoblast posted Ryoncil net revenue of US$36 million for the quarter ended June 30, 2026; US$115 million for the first full year post-FDA approval.
• Second-half Ryoncil net revenue totaled US$66.5 million; full-year net operating cash spend was US$43.8 million.
• Second-half operating cash spend was US$13.4 million; cash on hand was US$103 million at June 30, 2026.
• Drew US$50 million from a five-year facility to extinguish all maturing debt obligations.
• Commenced a registrational trial to extend Ryoncil into adults with steroid-refractory acute GvHD; up to 40 U.S. sites planned.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607292057PRIMZONEFULLFEED9800691) on July 30, 2026, and is solely responsible for the information contained therein.